Small Molecule Drug Discovery Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Small Molecule Drug Discovery Market Size Analysis

Global Small Molecule Drug Discovery Market Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value

North America Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value
U.S.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Synthetic Small Molecules
    1. By Value
  3. Natural-Product Derivatives
    1. By Value
  4. Peptide Mimetics
    1. By Value
  5. Nucleoside Analogues
    1. By Value
  6. Other Drug Types
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-throughput Screening
    1. By Value
  3. Fragment-based Drug Discovery
    1. By Value
  4. Structure-based Drug Design
    1. By Value
  5. Bioassay Development & Cell-based Platforms
    1. By Value
  6. CRISPR-based Target Validation
    1. By Value
  7. DNA-encoded library screening
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Biotechnology Companies
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Contract Research Organizations
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value
U.K.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Synthetic Small Molecules
    1. By Value
  3. Natural-Product Derivatives
    1. By Value
  4. Peptide Mimetics
    1. By Value
  5. Nucleoside Analogues
    1. By Value
  6. Other Drug Types
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-throughput Screening
    1. By Value
  3. Fragment-based Drug Discovery
    1. By Value
  4. Structure-based Drug Design
    1. By Value
  5. Bioassay Development & Cell-based Platforms
    1. By Value
  6. CRISPR-based Target Validation
    1. By Value
  7. DNA-encoded library screening
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Biotechnology Companies
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Contract Research Organizations
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value
China
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Synthetic Small Molecules
    1. By Value
  3. Natural-Product Derivatives
    1. By Value
  4. Peptide Mimetics
    1. By Value
  5. Nucleoside Analogues
    1. By Value
  6. Other Drug Types
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-throughput Screening
    1. By Value
  3. Fragment-based Drug Discovery
    1. By Value
  4. Structure-based Drug Design
    1. By Value
  5. Bioassay Development & Cell-based Platforms
    1. By Value
  6. CRISPR-based Target Validation
    1. By Value
  7. DNA-encoded library screening
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Biotechnology Companies
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Contract Research Organizations
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value
UAE
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Synthetic Small Molecules
    1. By Value
  3. Natural-Product Derivatives
    1. By Value
  4. Peptide Mimetics
    1. By Value
  5. Nucleoside Analogues
    1. By Value
  6. Other Drug Types
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-throughput Screening
    1. By Value
  3. Fragment-based Drug Discovery
    1. By Value
  4. Structure-based Drug Design
    1. By Value
  5. Bioassay Development & Cell-based Platforms
    1. By Value
  6. CRISPR-based Target Validation
    1. By Value
  7. DNA-encoded library screening
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Biotechnology Companies
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Contract Research Organizations
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Synthetic Small Molecules
  1. By Value
3. Natural-Product Derivatives
  1. By Value
4. Peptide Mimetics
  1. By Value
5. Nucleoside Analogues
  1. By Value
6. Other Drug Types
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-throughput Screening
  1. By Value
3. Fragment-based Drug Discovery
  1. By Value
4. Structure-based Drug Design
  1. By Value
5. Bioassay Development & Cell-based Platforms
  1. By Value
6. CRISPR-based Target Validation
  1. By Value
7. DNA-encoded library screening
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical Companies
  1. By Value
3. Biotechnology Companies
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Contract Research Organizations
  1. By Value
Brazil
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Synthetic Small Molecules
    1. By Value
  3. Natural-Product Derivatives
    1. By Value
  4. Peptide Mimetics
    1. By Value
  5. Nucleoside Analogues
    1. By Value
  6. Other Drug Types
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-throughput Screening
    1. By Value
  3. Fragment-based Drug Discovery
    1. By Value
  4. Structure-based Drug Design
    1. By Value
  5. Bioassay Development & Cell-based Platforms
    1. By Value
  6. CRISPR-based Target Validation
    1. By Value
  7. DNA-encoded library screening
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Biotechnology Companies
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Contract Research Organizations
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Small Molecule Drug Discovery Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Evotec SE
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
WuXi AppTec
ChemPartner
Atomwise Inc.
Pfizer Inc.
Eli Lily
Novartis AG
AstraZeneca
Insilico Medicine
Schrödinger, Inc.
Eurofins Discovery
Charles River Laboratories
Labcorp
GenScript Biotech
ICON plc
GSK plc
Lilly
Innovent Biologics, Inc.
Takeda Pharmaceutical Co Ltd
Terray Therapeutics
Excelsior Sciences

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment